Review
Oct 2026
Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.
Iza-bren significantly improved progression-free survival versus chemotherapy, and median progression-free survival assessed by Blinded Independent Central Review was 8·2 months (95% CI 6·9-8·6) versus 4·0 months (2·9-4·3; HR 0·41 [95% CI 0·33-0·53).
B. Lan, Ye-Hui Shi, Xi-Ying Shao et al.
· The Lancet · 0 citations